HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dimitri E Grigoriadis Selected Research

valbenazine

1/2020Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
1/2018VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).
9/2017Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.
1/2017Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dimitri E Grigoriadis Research Topics

Disease

4Tardive Dyskinesia
01/2020 - 01/2017
2Inflammation (Inflammations)
03/2013 - 09/2006
2Cocaine-Related Disorders (Cocaine Addiction)
09/2006 - 01/2005
2Mood Disorders (Mood Disorder)
04/2004 - 09/2002
2Shock
06/2003 - 08/2002
1Schizophrenia (Dementia Praecox)
01/2022
1Weight Gain
01/2022
1Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
03/2016
1Ulcerative Colitis
03/2013
1Cognitive Dysfunction
09/2010
1Hyperphagia (Overeating)
11/2009
1Anxiety Disorders (Anxiety Disorder)
09/2007
1Stomach Neoplasms (Stomach Cancer)
12/2006
1Diarrhea
09/2006
1Colitis
09/2006
1Sleep Initiation and Maintenance Disorders (Insomnia)
11/2004
1Hyperalgesia
09/2003
1Endotoxemia
06/2003

Drug/Important Bio-Agent (IBA)

4valbenazineIBA
01/2020 - 01/2017
4Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA
03/2013 - 06/2003
3Antipsychotic Agents (Antipsychotics)IBA
01/2022 - 01/2018
3Neurotransmitter Agents (Neurotransmitter)IBA
01/2020 - 04/2004
3Corticotropin-Releasing HormoneIBA
03/2016 - 06/2003
2Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA
01/2022 - 01/2020
2Pharmaceutical PreparationsIBA
01/2018 - 09/2007
2Adrenocorticotropic Hormone (ACTH)FDA Link
11/2009 - 06/2003
2Peptides (Polypeptides)IBA
01/2005 - 04/2004
1Risperidone (Risperdal Consta)FDA LinkGeneric
01/2022
1Olanzapine (Zyprexa)FDA Link
01/2022
1Dopamine (Intropin)FDA LinkGeneric
01/2022
1dihydrotetrabenazineIBA
01/2022
1Phencyclidine (Angel Dust)IBA
01/2020
1CRF receptor type 2IBA
03/2013
1NBI-34041IBA
09/2007
1Biological ProductsIBA
12/2006
1Anti-Bacterial Agents (Antibiotics)IBA
09/2006
1Chemotactic FactorsIBA
09/2006
1Cocaine (Cocaine HCl)IBA
09/2006
1Enterotoxins (Enterotoxin)IBA
09/2006
1Messenger RNA (mRNA)IBA
09/2006
1ChemokinesIBA
09/2006
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
09/2006
1Clostridium difficile tcdA proteinIBA
09/2006
1Hypnotics and Sedatives (Sedatives)IBA
11/2004
1Therapeutic UsesIBA
11/2004
1gamma-Aminobutyric Acid (GABA)IBA
11/2004
1BenzodiazepinesIBA
11/2004
1GABA-A Receptors (GABA(A) Receptor)IBA
11/2004
1indiplonIBA
11/2004
1Hormones (Hormone)IBA
04/2004
16- cyclopropylmethyl- 2- (2,4- dichlorophenyl)- 7- ethyl- 4- methyl- 7,8- dihydro- 6H- 1,3,6,8a- tetraazaacenaphthyleneIBA
09/2003
1CRF receptor type 1IBA
09/2003
1R 121919IBA
08/2002
1Anti-Anxiety Agents (Anxiolytics)IBA
08/2002

Therapy/Procedure

1Therapeutics
09/2002